UK 22:41 Wednesday, 30 September 2026
Breaking news and expert analysis on fast-moving AIM and LSE listed shares
The downfall of MGC Pharmaceuticals (MXC) has been well documented on this website since I published a detailed dossier 18 months ago when it was valued at £70million. Those who backed its founder Roby Zomer rather than my analysis have lost 99% of their moolah. But MGC looks like a great British success compared to Zomer’s other effort, Graft Polymer (GPL), floated at 21.5p less than two years ago, its shares are just 0.16p after another disaster today.
Graft Polymer (GPL) has announced an equity raise which is stated as “follows a year where we have made significant progress including the completion of our new commercial production facility in June 2023 and momentum with new contracts reflecting our competitive advantage based on strong innovation. We now have core infrastructure in place with established industry networks and the commitment of cornerstone investors. We look forward to delivering the next stage of growth”. So a competitive equity raise price relative to the prior closing share price, then?
Graft Polymer (GPL) has announced it has been contracted to produce a patented haemostatic powder following a recent successful pilot scheme and with its production facility in Slovenia now fully operational. What of the shares currently approaching 3p, up over 30%, in response?
Graft Polymer (GPL) states that it “is pleased to announce its audited results for the 12 months to 31 December 2022” and that it “continue to establish the stepping stones for growth and look forward to reporting our progress to shareholders during 2023”. So what of the shares currently responding to 5.5p, more than 30% lower?!
